{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Van der Vreken A"],"funding":["Ghent University","Catharina Weekers","Kom op tegen Kanker","Willy Gepts","Fonds Wetenschappelijk Onderzoek","Vrije Universiteit Brussel","King Baudouin Foundation"],"pagination":["e010673"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12049997"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(4)"],"pubmed_abstract":["<h4>Background</h4>Invariant natural killer T (iNKT) cells and CD8<sup>+</sup> T cells are key in the immune response against multiple myeloma (MM), a largely incurable blood cancer. Immunization is a promising strategy to activate these T cell populations. To our knowledge, immunization with messenger RNA (mRNA) and the iNKT agonist, α-galactosylceramide (αGC), has not been studied in MM, as knowledge on clinically relevant antigens in preclinical MM models is lacking.<h4>Methods</h4>Microarray data and immunopeptidomics (imPep) were used to identify candidate antigens for immunization in 5TMM models. Galsomes, lipid nanoparticles containing antigen mRNA and αGC were used to immunize 5T33MM-bearing mice. This treatment was combined with a CD40 agonist. Tumor burden and activation of iNKT "],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy."],"pmcid":["PMC12049997"],"funding_grant_id":["1164918N","1S73122N","12AN524N","FAF-C/2018/1213","2020-J1811380-217916","SRP48","G040319N","1275023N","SRP84","WFWG2019","12I0921N","K110324N","BOF21/GOA/033","BOF/STA/202209/011"],"pubmed_authors":["Mwangi K","Vanderkerken K","Tu C","Verbeke R","Menu E","Janssens E","Lentacker I","Franceschini L","De Bruyne E","Van der Vreken A","Thery F","Impens F","Meulewaeter S","Breckpot K","De Beck L","De Veirman K"],"additional_accession":[]},"is_claimable":false,"name":"Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.","description":"<h4>Background</h4>Invariant natural killer T (iNKT) cells and CD8<sup>+</sup> T cells are key in the immune response against multiple myeloma (MM), a largely incurable blood cancer. Immunization is a promising strategy to activate these T cell populations. To our knowledge, immunization with messenger RNA (mRNA) and the iNKT agonist, α-galactosylceramide (αGC), has not been studied in MM, as knowledge on clinically relevant antigens in preclinical MM models is lacking.<h4>Methods</h4>Microarray data and immunopeptidomics (imPep) were used to identify candidate antigens for immunization in 5TMM models. Galsomes, lipid nanoparticles containing antigen mRNA and αGC were used to immunize 5T33MM-bearing mice. This treatment was combined with a CD40 agonist. Tumor burden and activation of iNKT ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-02T17:33:38.206Z","creation":"2025-07-04T03:06:05.273Z"},"accession":"S-EPMC12049997","cross_references":{"pubmed":["40300855"],"doi":["10.1136/jitc-2024-010673"]}}